Angiotensin-converting enzyme 2 activation suppresses pulmonary vascular remodeling by inducing apoptosis through the Hippo signaling pathway in rats with pulmonary arterial hypertension

References

• Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S. The cancer theory of pulmonary arterial hypertension. Pulm Circ. 2017;7(2):285–99. Cited in PubMed; PMID:28597757. doi:10.1177/2045893217701438.
   PubMed Web of Science ®Google Scholar
• Shenoy V, Qi Y, Katovich MJ, Raizada MK. Ace2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol. 2011;11(2):150–55. doi:10.1016/j.coph.2010.12.002. Cited in PubMed; PMID: 21215698.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Fleg JJ, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, et al. Accf/aha 2011 expert consensus document on hypertension in the elderly: a report of the American college of cardiology foundation task force on clinical expert consensus documents. J Am Soc Hypertens. 2011;5(4):259–352. doi:10.1016/j.jash.2011.06.001. Cited in PubMed; PMID: 21771565.
   PubMed Web of Science ®Google Scholar
• Sakao S, Tatsumi K, Voelkel NF. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Resp res. 2009;10(1):95. doi:10.1186/1465-9921-10-95. Cited in PubMed; PMID:19825167.
   PubMedGoogle Scholar
• Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4(4):291–305. doi:10.1016/S2213-2600(16)00027-8. Cited in PubMed; PMID:26935844.
   PubMed Web of Science ®Google Scholar
• Li G, Liu YL, Zhu YB, Liu AJ, Xu YL, Li XF, Li ZQ, Su JW, Sun LZ. Ace2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung. 2013;191(4):327–36. doi:10.1007/s00408-013-9470-8. Cited in PubMed; PMID:23652350.
   PubMed Web of Science ®Google Scholar
• Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, Yamazato M, Yuan L, Bradford CN, Shenoy V, Oh SP, et al. Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension. 2009;54(2):365. doi:10.1161/HYPERTENSIONAHA.108.125468. Cited in PubMed; PMID:19564552.
   PubMed Web of Science ®Google Scholar
• Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(11):1048–54. doi:10.1164/rccm.200811-1678OC. Cited in PubMed; PMID:19246717.
   PubMed Web of Science ®Google Scholar
• Erzurum S, Rounds SI, Stevens T, Aldred M, Aliotta J, Archer SL, Asosingh K, Balaban R, Bauer N, Bhattacharya J, et al. Strategic plan for lung vascular research: an NHLBI-ORDR workshop report. Am J Respir Crit Care Med. 2010;182(12):1554–62. doi:10.1164/rccm.201006-0869WS. Cited in PubMed; PMID:20833821.
   PubMed Web of Science ®Google Scholar
• Goncharov DA, Kudryashova TV, Ziai H, Ihida-Stansbury K, DeLisser H, Krymskaya VP, Tuder RM, Kawut SM, Goncharova EA. Mammalian target of rapamycin complex 2 (mtorc2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension. Circulation. 2014;129(8):864–74. doi:10.1161/CIRCULATIONAHA.113.004581. Cited in PubMed; PMID:24270265.
   PubMed Web of Science ®Google Scholar
• Li YC, Cao YM, Zeng Z, Liang MF, Xue Y, Xi CH, Zhou M, Jiang W. Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep. 2015;5:8209. doi:10.1038/srep08209. Cited in PubMed: PMID:25644821.
   PubMed Web of Science ®Google Scholar
• Wang LF, Wang YX, Yang T, Guo YF, Sun TY. Angiotensin-converting enzyme 2 attenuates bleomycin-induced lung fibrosis in mice. Cell Physiol Biochem. 2015;36(2):697–711. doi:10.1159/000430131. Cited in PubMed: PMID:25998889.
   PubMed Web of Science ®Google Scholar
• Young D, Waitches G, Birchmeier C, Fasano O, Wigler M. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell. 1986;45(5):711–19. Cited in PubMed; PMID:3708691.
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao JG, Yuan HX, Tumaneng K, Li HR, et al. Regulation of the hippo-yap pathway by g-protein-coupled receptor signaling. Cell. 2012;150(4):780–91. doi:10.1016/j.cell.2012.06.037. Cited in PubMed; PMID:22863277.
   PubMed Web of Science ®Google Scholar
• Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development. 2011;138(1):9–22. doi:10.1242/dev.045500. Cited in PubMed; PMID:21138973.
   PubMed Web of Science ®Google Scholar
• Ehmer U, Sage J. Control of proliferation and cancer growth by the hippo signaling pathway. Mol Cancer Res. 2016;14(2):127–40. doi:10.1158/1541-7786.MCR-15-0305. Cited in PubMed; PMID:26432795.
   PubMed Web of Science ®Google Scholar
• Zhao B, Wei XM, Li WQ, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu JD, Li L, et al. Inactivation of yap oncoprotein by the hippo pathway is involved in cell contact inhibition and tissue growth control. Gene Dev. 2007;21(21):2747–61. doi:10.1101/gad.1602907. Cited in PubMed; PMID:17974916.
   PubMed Web of Science ®Google Scholar
• Hao YW, Chun A, Cheung K, Rashidi B, Yang XL. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Bio Chem. 2007;283(9):5496–509. doi:10.1074/jbc.M709037200. Cited in PubMed; PMID:18158288.
   PubMed Web of Science ®Google Scholar
• Wennmann DO, Vollenbröker B, Eckart AK, Bonse J, Erdmann F, Wolters DA, Schenk LK, Schulze U, Kremerskothen J, Weide T, et al. The hippo pathway is controlled by angiotensin ii signaling and its reactivation induces apoptosis in podocytes. Cell Death Dis. 2014;5(11):e1519. doi:10.1038/cddis.2014.476. Cited in PubMed; PMID:25393475.
   PubMedGoogle Scholar
• Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol. 1997;151(4):1019–25. Cited in PubMed; PMID:9327735.
   PubMed Web of Science ®Google Scholar
• Fan F, He Z, Kong LL, Chen Q, Yuan Q, Zhang S, Ye J, Liu H, Sun X, Geng J, et al. Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration. Sci Transl Med. 2016;8(352):352ra108. doi:10.1126/scitranslmed.aaf2304. Cited in PubMed; PMID:27535619.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003;108(13):1640–45. doi:10.1161/01.CIR.0000087592.47401.37. Cited in PubMed; PMID:12963647.
   PubMed Web of Science ®Google Scholar
• Gurbanov E, Xie SL. The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. Eur J Cardio-Thorac. 2006;30(3):499–507. doi:10.1016/j.ejcts.2006.05.026. Cited in PubMed; PMID:16870458.
   PubMed Web of Science ®Google Scholar
• Li G, Xu YL, Ling F, Liu AJ, Wang D, Wang Q, Liu YL. Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels. Chin Med J. 2012;125(8):1381–88. doi:10.3760/cma.j.issn.0366-6999.2012.08.004. Cited in PubMed; PMID:22613639.
   PubMed Web of Science ®Google Scholar
• Dickinson MG, Bartelds B, Borgdorff MA, Berger RM. The role of disturbed blood flow in the development of pulmonary;arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol. 2013;305(1):L1–L14. doi:10.1152/ajplung.00031. Cited in PubMed; PMID:23624788.
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115(6):1479–91. doi:10.1172/JCI23203. Cited in PubMed; PMID:15931388.
   PubMed Web of Science ®Google Scholar
• Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated t cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA. 2007;104(27):11418–23. doi:10.1073/pnas.0610467104. Cited in PubMed; PMID:17596340.
   PubMed Web of Science ®Google Scholar
• Uhal BD, Dang M, Dang V, Llatos R, Cano E, Abdul-Hafez A, Markey J, Piasecki CC, Molina-Molina M. Cell cycle dependence of ace-2 explains downregulation in idiopathic pulmonary fibrosis. Eur Respir J. 2013;42(1):198–210. doi:10.1183/09031936.00015612. Cited in PubMed; PMID:23100504.
   PubMed Web of Science ®Google Scholar
• Cheng QJ, Zhou L, Zhou JP, Wan HY, Li QY, Feng Y. Ace2 overexpression inhibits acquired platinum resistance-induced tumor angiogenesis in nsclc. Oncol Rep. 2016;36(3):1403–10. doi:10.3892/or.2016.4967. Cited in PubMed; PMID:27460845.
   PubMed Web of Science ®Google Scholar
• Liu YP, Li B, Wang XM, Li GS, Shang R, Yang JM, Wang JL, Zhang M, Chen YG, Zhang Y, et al. Angiotensin-(1–7) suppresses hepatocellular carcinoma growth and angiogenesis via complex interactions of angiotensin II type 1 receptor, angiotensin II type 2 receptor and mas receptor. Mol Med. 2015;21(1):626–36. doi:10.2119/molmed.2015.00022. Cited in PubMed; PMID:26225830.
   PubMedGoogle Scholar
• Luo Y, Tanabe E, Kitayoshi M, Nishiguchi Y, Fujiwara R, Matsushima S, Sasaki T, Sasahira T, Chihara Y, Nakae D, et al. Expression of mas1 in breast cancer. Cancer Sci. 2015;106(9):1240–48. doi:10.1111/cas.12719. Cited in PubMed; PMID:26080617.
   PubMed Web of Science ®Google Scholar
• Meng ZP, Moroishi T, Guan KL. Mechanisms of hippo pathway regulation. Genes Dev. 2016;30(1):1–17. doi:10.1101/gad.274027.115. Cited in PubMed; PMID:26728553.
   PubMed Web of Science ®Google Scholar
• He JL, Bao QK, Yan M, Liang J, Zhu Y, Wang CJ, Ai D. The role of hippo/yes‐associated protein signalling in vascular remodelling associated with cardiovascular disease. Br J Pharmacol. 2017;175(8):1354–61. doi:10.1111/bph.13806. Cited in PubMed; PMID:28369744.
   PubMed Web of Science ®Google Scholar
• Bertero T, Oldham WM, Cottrill KA, Pisano S, Vanderpool RR, Yu Q, Zhao J, Tai Y, Tang Y, Zhang YY, et al. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J Clin Invest. 2016;126(9):3313–35. doi:10.1172/JCI86387. Cited in PubMed; PMID:27548520.
   PubMed Web of Science ®Google Scholar
• Bertero T, Cottrill KA, Lu Y, Haeger CM, Dieffenbach P, Annis S, Hale A, Bhat B, Kaimal V, Zhang YY, et al. Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP/TAZ-miR-130/301 circuit. Cell Rep. 2015;13(5):1016–32. doi:10.1016/j.celrep.2015.09.049. Cited in PubMed; PMID:26565914.
   PubMed Web of Science ®Google Scholar
• Kudryashova TV, Goncharov DA, Pena A, Kelly N, Vanderpool R, Baust J, Kobir A, Shufesky W, Mora AL, Morelli AE, et al. Hippo-integrin linked kinase crosstalk controls self-sustaining proliferation and survival in pulmonary hypertension. Am J Respir Crit Care Med. 2016;194(7):866–77. doi:10.1164/rccm.201510-2003OC. Cited in PubMed; PMID:27119551.
   PubMed Web of Science ®Google Scholar
• Rosenbluh J, Nijhawan D, Cox AG, Li XN, Neal JT, Schafer EJ, Zack TI, Wang XX, Tsherniak A, Schinzel AC, et al. β-Catenin-driven cancersrequire a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457–73. doi:10.1016/j.cell.2012.11.026. Cited in PubMed; PMID:23245941.
   PubMed Web of Science ®Google Scholar
• Wang MY, Chen PS, Prakash E, Hsu HC, Huang HY, Lin MT, Chang KJ, Kuo ML. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 2009;69(8):3482–91. doi:10.1158/0008-5472.CAN-08-2524. Cited in PubMed; PMID:19351859.
   PubMed Web of Science ®Google Scholar
• Arciniegas E, Neves CY, Carrillo LM, Zambrano EA, Ramírez R. Endothelial-Mesenchymal transition occurs during embryonic pulmonary artery development. Endothelium. 2005;12(4):193–200. doi:10.1080/10623320500227283. Cited in PubMed; PMID:16162442.
   PubMed Web of Science ®Google Scholar